| Literature DB >> 29955512 |
P Brittany Vickery1, Lindsy Meadowcraft2, Stephen B Vickery3.
Abstract
Neuroleptic malignant syndrome (NMS), which is considered a neurologic emergency, is believed to be caused by exposure to dopamine antagonist or withdrawal from a dopamine agonist. This article reports a case of suspected atypical NMS in a patient following rapid conversion of ziprasidone to risperidone without titration. While the initial presentation did not fully meet the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, diagnostic features, a sequential treatment strategy was initiated and the patient appropriately responded to antipsychotic cessation in addition to combination therapy with dantrolene and bromocriptine. Neuroleptic malignant syndrome diagnostic criteria, treatment, and prognosis are discussed.Entities:
Keywords: NMS; antipsychotic; bromocriptine; catatonia; dantrolene; fluoxetine; neuroleptic malignant syndrome; risperidone; ziprasidone
Year: 2018 PMID: 29955512 PMCID: PMC6007570 DOI: 10.9740/mhc.2017.05.137
Source DB: PubMed Journal: Ment Health Clin ISSN: 2168-9709